Navigation Links
Cordex Pharma Forms Heart Failure Medical Advisory Board
Date:2/11/2009

s perhaps one of the largest untapped pharmaceutical markets. Currently available drugs prolong the lives of patients with this condition, however, surprisingly little innovative research is being translated to new medicines. With the help of our Medical Advisory Board, we hope to demonstrate the clinical safety and efficacy of CDP-1050 in an efficient and convincing manner to the satisfaction of the medical community and regulatory authorities alike. Eventually, we hope to make the drug available to treat the desperately ill heart failure patients worldwide."

About Heart Failure

Heart failure, a condition characterized by the inability of the heart to effectively pump blood as well as by fluid accumulation in the lungs and other tissues, is suffered by an estimated five million Americans and is responsible for 300,000 deaths in the U.S. annually, according to the National Heart, Lung and Blood Institute. It is the single largest Medicare expense, at a cost of $33.2 billion each year. The five-year mortality rate with heart failure can be as high as 50 percent.

About CDP-1050

CDP-1050 is an investigational drug candidate for the treatment of heart failure. The drug is designed to correct the nitric oxide and redox imbalance in the failing heart and the cardiovascular system. CDP-1050 has a dual mechanism of action; it inhibits the production of excessive reactive oxygen radicals and restores nitric oxide to physiologic levels. The primary therapeutic target is the ryanodine receptor, the main ion channel in the heart that supplies the calcium necessary for the heart to contract. CDP-1050 is expected to enter a Phase 2 clinical trial this year.

About Cordex Pharma, Inc.

Cordex is a specialty pharmaceutical company that develops new cardiovascular medicines based upon the emerging pharmacology of adenosine triphosphate (ATP) and nitric oxide (NO). These two
'/>"/>

SOURCE Cordex Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cordex Pharma Presents New Frontiers in Cardiovascular Medicines on January 29
2. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
3. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
6. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2015)... March 25, 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or ... a result of recent discussions with certain shareholders representing ... the Company, after dealing with certain matters including the ... of shareholders on March 26, 2015 (the "Meeting") it ... of directors will take place when the Meeting reconvenes. ...
(Date:3/25/2015)... Laboratory workers can turn to ... Balances to get best-performing features while still remaining ... from the trusted brand include: , Cole-Parmer ... efficiency by providing a large weighing surface for ... include parts counting, percent weighing, checkweighing, animal/dynamic weighing, ...
(Date:3/25/2015)... CORAL SPRINGS, Fla. , March 25, 2015 ... (HIT) strategy and management consulting firm, has launched ... reference publication to simplify tracking of ePrescribing regulatory ... "The ePrescribing regulatory landscape continues to ... offerings to deliver what the industry, and ultimately ...
(Date:3/25/2015)... LOUIS and the HAGUE, Netherlands ... of two-year results of LES Stimulation therapy for chronic ... the journal Surgery [ Surgery . ... efficacy of its minimally-invasive therapy. The ... average duration of 11 years and taking prescribed daily ...
Breaking Biology Technology:SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 2SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 3SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 4SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 5New Economical Top-Loading and Analytical Symmetry Balances from Cole-Parmer 2Point-of-Care Partners Launches the ePrescribing State Law Capsule 2EndoStim LES Stimulation therapy demonstrates long term safety and efficacy results in treating reflux patients 2EndoStim LES Stimulation therapy demonstrates long term safety and efficacy results in treating reflux patients 3
... 9, 2011 Rhythm announced today results demonstrating that ... in restoring normal gastric function in animal models of ... The results were the subject of an oral presentation ... Harvard Medical School) titled "RM-131: A Potent Gastroprokinetic Agent" ...
... BD Diagnostics, a segment of global medical technology ... BDX ), and Diagenode SA, an international biotech company ... seven initial molecular diagnostic assays on the BD MAX™ ... nervous system diseases.   "Our agreement with ...
... 9, 2011 caprotec bioanalytics GmbH, a ... Mass Spectrometry (CCMS) platform technology for the analysis of ... closing of EUR 1 million ($1.4 M) to its ... to EUR 5 million ($7.2 M). The capital increase ...
Cached Biology Technology:Rhythm's RM-131 Restores GI Function as a Potent Ghrelin Prokinetic 2BD and Diagenode Collaborate to Expand Infectious Disease Menu on the BD MAX™ System 2BD and Diagenode Collaborate to Expand Infectious Disease Menu on the BD MAX™ System 3BD and Diagenode Collaborate to Expand Infectious Disease Menu on the BD MAX™ System 4caprotec bioanalytics Increases Series B Financing in Second Closing to EUR 5 Million 2
(Date:3/17/2015)...  MecklerMedia Corporation (OTCQX: MECK) announced its ... ever held in New York City ... 2015 at the Javits Convention Center. ... Acorn Product Development; Axis NJ; c-Link Systems; CoroWare; ... NewBotic Corporation; Neya Systems LLC; Reliabotics; RoboKind; RocketFarm ...
(Date:3/12/2015)... FAIRFAX, Va. , March 12, 2015 ... company and a member of the Texas Instruments Design ... Chandrababu Naidu has demonstrated its IriShield USB MK2120U ... iris scanning facility for pension distribution. ... and assembled to be marketed in India ...
(Date:3/12/2015)... 2015 Beta Systems today ... access management (IAM) solution for a fixed price ... System,s new IAM package, customers benefit from the ... multiple IAM implementations across different industries. The new ... as any necessary services and consulting. It spans ...
Breaking Biology News(10 mins):MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 2Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 3Beta Systems Fast Forward IAM Available Now: a Standardized IAM Package at a Fixed Price 2
... WASHINGTON, D.C.-- In a major step that could revolutionize biomedical ... as well as tumor cells taken from an individual cancer ... been possible. Normal cells usually die in the lab after ... not grow, unaltered, outside of the body. This new ...
... throughout the Northern Hemisphere for more than a century and ... lakes located thousands of miles from the nearest city, industrial ... Science Dec. 16, are based on historical changes ... using an approach similar to aquatic archeology. More than three ...
... risk of attack has led to the development of ... larval stage. One caterpillar may look like a stick, ... may have its advantages, University of Florida researchers uncovered ... another strategy previously best-known in adult butterflies: mimicry. ...
Cached Biology News:Georgetown researchers lead discovery expected to significantly change biomedical research 2Nitrogen from humans pollutes remote lakes for more than a century 2Nitrogen from humans pollutes remote lakes for more than a century 3Caterpillars mimic one another for survival 2Caterpillars mimic one another for survival 3
...
... assay (ELISA) test kits are qualitative one-step ... detection of drugs and/or their metabolites in ... forensic use only. It is recommended that ... quantitative method such as GC/MS. The ...
96 Well Base Plate...
... Inhibitor is a recombinant human protein produced in ... neutral pancreatic RNase A type enzymes. The ... binds RNases in a 1:1 ratio. The enzyme ... many tissues and cell types. Addition of the ...
Biology Products: